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ss in past years, the Associate Editors have assembled this
ighlights article. We included those papers published in
he Journal in the past 12 months that we perceived as
aving the greatest impact on cardiology. Space constraints
esulted in omitting many excellent papers, for which we
pologize in advance to the authors.
nterventional Cardiology
irst Reports of New Randomized Clinical Trials
nprotected left main coronary artery intervention. The
ole of percutaneous coronary intervention (PCI) in unpro-
ected left main coronary artery stenosis in the current era is
ot well defined. Erglis et al. (1), in a relatively small study,
andomized 103 patients to receive either bare-metal stents
BMS) or paclitaxel-eluting stents (PES) (n  53). Lesions
ere pre-treated with cutting balloons, and stent placement
as guided with intravascular ultrasound (IVUS). At 6
onths, PES had less binary restenosis (6% vs. 22%, p 
.02), less neointima volume (17% vs. 25%, p  0.02), and
reater major adverse cardiac event (MACE)-free survival
87 vs. 70, p  0.03). These results need validation but
uggest favorable outcomes in left main coronary artery
nterventions with drug-eluting stents (DES).
T-segment elevation myocardial infarction (STEMI). The
ole of DES in STEMI is still evolving. The SESAMI
Sirolimus-Eluting Stent Versus Bare-Metal Stents in
cute Myocardial Infarction) trial (2) randomized 320
TEMI patients to sirolimus-eluting stents (SES) or BMS.
t 1 year, the primary end point of binary restenosis
ccurred in 9% in SES versus 21% in BMS, p  0.03.
arget lesion revascularization (TLR) (4% vs. 11%, p 
.02), target vessel revascularization (TVR) (5% vs. 13%, p
rom the *Cardiology Division and §Emeritus University of California–San Diego,
an Diego, California; †Leiden University Medical Center, Leiden, the Netherlands;
Duke University, Durham, North Carolina; Veterans Affairs Medical Center, San
iego, California; ¶Johns Hopkins Hospital, Baltimore, Maryland; #Cardiologye
ivision, University of California Irvine, Irvine, California; and **Pediatric Cardiol-
gy, Oregon Health and Science University, Portland, Oregon.0.01), MACE (6% vs. 16%, p  0.005), and target vessel
ailure (8% vs. 18%, p  0.007) were also lower with SES.
The RELAx-AMI (Randomized Early Versus Late Ab-
iximab in Acute Myocardial Infarction Treated with Pri-
ary Coronary Intervention) trial (3) compared early
emergency room) versus late (catheterization laboratory)
bciximab administration in 210 STEMI patients. Primary
nd points were Thrombolysis In Myocardial Infarction
TIMI) flow grade, corrected TIMI frame count (cTFC),
yocardial blush grade (MBG), and echocardiographic left
entricular (LV) function recovery. The early group showed
etter parameters before as well as after PCI. Mean gain in
eft ventricular ejection fraction (LVEF) (8% vs. 6%, p 
.02) was also better in the early group. Although this study
as not powered for MACE, it strongly supports the
oncept that administration of abciximab in STEMI should
e performed as soon as possible.
roximal protection device. Distal protection devices re-
uce MACE in vein graft PCI, but proximal protection
evices may have procedural advantages in select lesions.
he PROXIMAL (Proximal Protection During Saphenous
ein Graft Interventions) trial (4) enrolled 594 patients
ndergoing stenting of 639 saphenous vein grafts using a
oninferiority design. The primary composite end point of
eath, myocardial infarction (MI), or TVR at 30 days by
ntention-to-treat analysis occurred in 10.0% of the distal
roup and 9.2% of the proximal group (p for noninferiority
0.006). Results were similar in device-specific analysis or
n patients with lesions amenable to treatment with either
roximal or distal devices. These findings indicate that
roximal embolic protection produced outcomes similar to
hose with distal protection for saphenous vein grafts.
enal protection during coronary angiography and
CI. Two randomized controlled trials (RCTs) described
ew methods for renal protection in high-risk coronary
ngiography or emergency PCI. Lee et al. (5) assigned 82
atients with baseline creatinine levels of 4.9 mg/dl to either
aline or prophylactic hemodialysis immediately after cath-
terization. Hemodialysis blunted the decrease in creatinine
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January 29, 2008:490–512 Highlights From JACC 2007learance within 72 h and led to significantly lower peak (5.3
g/dl vs. 6.7 mg/dl, p  0.005) and Day 4 (5.1 mg/dl vs.
.3 mg/dl, p  0.010) creatinine. Thirteen percent of the
ontrol patients but none of the dialysis patients required
ong-term dialysis after discharge (p  0.01). This study
uggests that one session of prophylactic hemodialysis is
ffective in improving renal outcome in chronic renal failure
atients undergoing coronary angiography.
Recio-Mayoral et al. (6) randomized 56 patients to sodium
icarbonate plus 2,400 mg intravenous N-acetylcysteine just
efore contrast injection and for 12 h after PCI (group A)
nd 55 patients to saline (group B). In both groups, 2 doses
f 600 mg oral N-acetylcysteine were administered the next
ay. A creatinine level 0.5 mg/dl from baseline after
mergency PCI was observed in 1 patient in group A (1.8%)
nd in 12 patients in group B (21.8%, p  0.001). Acute
nuric renal failure was observed in 1 patient (1.8%) in
roup A and in 7 patients (12.7%) in group B (p  0.03).
his study provides a rapid method for minimizing renal
njury in patients undergoing emergency PCI.
CI in high-risk groups: diabetic patients and complex
esions in the left anterior descending artery. Specific
CTs to evaluate the safety and efficacy of DES are now
eing reported. Baumgart et al. (7) randomized 200 patients
ith diabetes and de novo coronary artery lesions to SES
ersus BMS, with angiographic parameters as the primary
nd point. In-segment late luminal loss, in-segment reste-
osis, and TLR were lower with SES (p  0.0001). The
ES were effective in diabetic patients on oral agents and on
nsulin. At 12 months, the MACE rate was 14.7% in SES
ersus 35.8% in BMS. Petronio et al. (8) randomized 85
atients with complex lesions of the left anterior descending
rtery to SES or PES implantation. The primary end point,
ercent neointimal hyperplasia area (NIHA%) by intravas-
ular ultrasound at 9 month follow-up, was significantly
ower with SES than PES (7.4 vs. 15.4, p  0.001), as was
ate loss.
egistry Studies With DES
eal-world registries reflect both on-label and off-label
ndications of approved devices, and may more closely
epresent actual safety and efficacy than randomized studies.
hree important registries reported outcomes in patients
eceiving DES and suggested outcomes are at least equal if
ot better than with BMS. In the National Heart, Lung,
nd Blood Institute Dynamic Registry (9), patients receiv-
ng DES (n  1,460) had a lower rate of death/MI TVR
nd risk of any repeat revascularization compared with
MS. The 1-year incidence of stent thrombosis was 1.0% in
ES patients.
The STENT (Strategic Transcatheter Evaluation of New
herapies) registry (10) collected data on all PCIs in 8 U.S.
ospitals between 2003 and 2005. Patients who only re-
eived a PES (n  4,671) or SES (n  4,555) and
ompleted 9-month follow-up (93.8% of eligible) were
nalyzed. The investigators observed that death, MI, and aACE were similar with PES and SES in real-world
atients at 9 months. Similar data were noted in a smaller
egistry from Italy, which also analyzed late loss and
ngiographic restenosis (11).
-Year Outcomes of Landmark Trials
wo landmark studies reported 5-year outcomes. The
AVEL (Randomized Comparison of a Sirolimus-Eluting
tent With a Standard Stent for Coronary Revasculariza-
ion) trial (12) was the first RCT of DES and included 238
atients with a single de novo native stenosis treated with
ither SES or BMS. The 1-, 3-, and 5-year rates of survival
ree from TLR were 99.2%, 93.8%, and 89.7%, respectively,
n the SES group versus 75.9%, 75.0%, and 74.0% in the
MS group (p  0.001, log-rank). Rates of all MACE at 5
ears were 25.8% in patients treated with SES versus 35.2%
ith BMS (p  0.03, log-rank). Rates of stent thrombosis
ere similar in both groups. Although relatively small, this
tudy suggests a durable beneficial effect of DES up to 5
ears.
The DEFER (Deferral Versus Performance of PTCA in
atients Without Documented Ischemia) trial (13) mea-
ured fractional flow reserve (FFR) in 325 patients sched-
led for PCI of an intermediate stenosis. If FFR was0.75,
CI was performed as planned (n  144), whereas if FFR
as 0.75, patients were randomly assigned to deferral
DEFER, n  91) or performance (Perform, n  90) of
CI. The 5-year event-free survival was not different
etween the DEFER and Perform groups (80% and 73%),
ut was significantly worse in the Reference group (63%, p
0.03). The composite rate of cardiac death and acute MI
n the DEFER, Perform, and Reference groups was 3.3%,
.9%, and 15.7%, respectively (p  0.003 for the Reference
s. both other groups). Freedom from chest pain was not
imilar for the Defer and Perform groups. The investigators
oncluded that 5-year outcome after deferral of PCI of an
ntermediate coronary stenosis based on FFR 0.75 is
xcellent.
ES Thrombosis and Restenosis
llis et al. (14) performed a patient-based meta-analysis of
he 4 principal Taxus (Boston Scientific, Natick, Massachu-
etts) randomized trials (3,445 patients) with a follow-up
uration of 1 year. Cumulative stent thrombosis occurred
n 1.28% in the Taxus group and 0.76% in the BMS group
t 3 years (hazard ratio 1.51, p  0.26). Hazard ratios (per
00 patients per 6 months) were similar in PES versus BMS
uring the prescribed clopidogrel period, with approxi-
ately 0.8% risk of stent thrombosis. From 6 months to 3
ears there were more stent thromboses in the Taxus group
hazard ratio 0.19 vs. 0.02, p  0.05).
Dibra et al. (15) performed a meta-analysis of 4 random-
zed studies comparing SES and PES versus balloon angio-
lasty or vascular brachytherapy in 1,230 patients with BMS
n-stent restenosis. No significant heterogeneity was found
cross trials. The risk of TLR (odds ratio 0.35) and
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Highlights From JACC 2007 January 29, 2008:490–512ngiographic restenosis (odds ratio 0.36) (both p  0.001),
ut not death or MI, were markedly lower with DES. It was
oncluded that DES should be considered as first-line
reatment for patients with BMS in-stent restenosis.
The natural history of DES in-stent restenosis and stent
hrombosis is not well known. Mishkel et al. (16) evaluated
utcomes of 92 patients who developed restenosis (n  84)
r thrombosis (n  8) inside DES. Patients were treated by
he DES sandwich technique or by other methods. Over a
ean follow-up of 15 months, the overall rates of death,
I, and TLR were 8.7%, 2.2%, and 30.6%, respectively. By
ctuarial analysis, the 12-month TLR and MACE rates
ere 28.2% and 42.9%, respectively. The investigators
oncluded that DES in-stent restenosis and stent thrombo-
is are associated with a significant long-term rate of
ACE.
Two other studies documented that large thrombus
urden is an independent predictor of MACE and stent
hrombosis in patients treated with DES for STEMI (17),
nd that IVUS performed during PCI for DES stent
hrombosis generally shows thrombotic occlusion within an
nderexpanded stent (18).
lopidogrel Desensitization
lopidogrel hypersensitivity can have devastating conse-
uences in patients treated with DES. von Tiehl et al. (19)
escribe an apparently safe and effective outpatient method
o desensitize patients. The technique, supervised by a
edicated drug desensitization nurse and an allergist, in-
olves increasing oral doses of clopidogrel over 8 h, finally
eaching a dose of 75 mg. Only 4 of 24 patients had
eactions, mostly minor. The benefit persisted up to 6
onths. The investigators warn that even a brief period of
iscontinuation of clopidogrel after desensitization may
llow symptoms to recur once the drug is restarted.
esion Morphology With Advanced Imaging Techniques
ata are now accumulating showing that invasive tech-
iques can determine plaque composition, which has been
hown to determine risk of plaque rupture. Using IVUS
adiofrequency data, Valgimigli et al. (20) determined that
ecrotic core content was quite minimal in left main
oronary artery stenoses, but peaked in the first 6-mm left
nterior descending (LAD) coronary segment and then
rogressively decreased distally. This is consistent with
ngiographic studies suggesting that most MIs occur in the
roximal one-third of coronary arteries. Furthermore,
awamoto et al. (21) showed that necrotic core content was
ssociated with embolization of small embolic particles and
educed coronary flow reserve. Finally, Kubo et al. (22)
ompared culprit lesion morphology with IVUS, coronary
ngioscopy, and optical coherence tomography, and sug-
ested that optical coherence tomography may identify
laque rupture fibrous cap erosion, intracoronary thrombus,
nd thin cap fibroatheromas more frequently compared with
he other techniques. These invasive imaging techniques rill ultimately need to show the ability to predict the benefit
f therapeutic interventions and predict clinical events to
ave greater clinical utility.
ardiac Imaging
ardiac Computed Tomography (CT)
he Journal published the first studies looking at the
rognostic power of computed tomographic angiography
CTA). In a study by Min et al. (23), the severity of
therosclerosis represented as number and location of seg-
ents involved with lesions as well as location and type of
therosclerotic plaque were correlated with all-cause mor-
ality in 1,127 patients followed up for 15.3 months on
verage. Clinical scores measuring plaque burden and dis-
ribution predicted a higher absolute death rate (6.6% vs.
.6% and 8.4% vs. 2.5%, p  0.05 for both). Similar studies
n the prognostic power of CTA showed a positive rela-
ionship between stenotic plaque and combined cardiac
vents (24) as well as between calcified plaque and all-cause
ortality (25). These studies, although single-center and
ocused on symptomatic or referred patients, reveal the
otential of CTA as a prognostic tool in patients with
uspected coronary artery disease (CAD).
The limitations of cardiac CTA in advanced CAD were
llustrated by a study looking at combined anatomical and
erfusion information from hybrid multidetector CTA/
ingle-photon emission computed tomography (SPECT) in
ymptomatic individuals with suspected CAD (26). The
ybrid approach increased the specificity and positive pre-
ictive value of detecting significant angiographic lesions
hat were associated with a corresponding perfusion defect.
iven the possibility of coupling multidetector CTA with
ositron emission tomography (PET) or SPECT, or even in
he future obtaining both sets of information from CT
lone, this pioneering study is thought provoking. Finally,
n an interesting study aimed at better defining which
atients with CAD are most likely to benefit, Meijboon et
l. (27) reported this year that multidetector CTA is most
seful in patients with a low to intermediate estimated
re-test probability of having significant CAD.
Although CTA has been shown to be accurate in the
dentification of coronary stenoses, the clinical utility of the
odality remains undefined. Goldstein et al. (28) conducted
n important RCT to assess the value of CTA in patients
ith acute chest pain syndromes. The investigators random-
zed nearly 200 patients to either immediate CTA or the
sual clinical evaluation for chest pain in the emergency
oom. No adverse events occurred in either patient group.
he CTA immediately identified coronary disease as the
robable source of the chest pain in 75% of patients,
hereas the remaining 25% required stress testing. Evalu-
tion by CTA reduced diagnostic time from 15 to 3.4 h and
owered costs from $1,870 to $1,580. Although these data
mpressively showed the ability of CTA in the emergency
oom to reduce the time and cost required to evaluate chest
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January 29, 2008:490–512 Highlights From JACC 2007ain, the accuracy in identifying CAD was identical for
TA and traditional evaluation, and no adverse events were
xperienced. In addition, a subset of patients was exposed to
adiographic procedures twice, and some on 3 occasions
immediate CTA, myocardial perfusion stress imaging, and
ardiac catheterization).
Data regarding the ability of CTA to identify stenoses in
tented coronary vessels has been lacking. Cademartiri et al.
29) took advantage of technological advances in CTA to
tudy 182 patients with intracoronary stents. Only 7.3% of
tented segments were excluded because of poor image
uality. In comparison with invasive coronary angiography,
TA exhibited a sensitivity and specificity of 95% and 93%
n diagnosing in-stent restenosis. Similiarly, Konen et al.
30) studied the prevalence of intramuscular coronary arter-
es as visualized by CTA. They identified 47 muscular
egments in 30.5% of patients evaluated, most located in the
id LAD. Prevalence of myocardial vessels observed was
reater than reported with angiography and concordant
ith pathological findings.
The use of CTA to diagnose CAD in patients presenting
ith HF was examined by Andreini et al. (31) in 61 dilated
ardiomyopathy patients who underwent both CTA and
nvasive coronary angiography. An excellent agreement
etween these 2 techniques for detection/exclusion of sig-
ificant coronary artery stenoses was observed (sensitivity
9%, specificity 96%). Recent studies have extended the use
f 64-slice CTA to evaluate patients with previous revascu-
arization either by stenting or coronary artery bypass graft
urgery. Ehara et al. (32) evaluated 81 patients with previous
ercutaneous coronary intervention and stent implantation
ith CTA and compared the results with invasive angiog-
aphy. A sensitivity and specificity of 92% and 81% were
eported to detect/exclude in-stent restenosis; when 15
ninterpretable segments were excluded from analysis, sen-
itivity remained unchanged, whereas specificity increased
o 91%.
Meyer et al. (33) evaluated 138 patients with previous
ypass surgery with CTA; 98% of grafts were adequately
isualized on multislice CT. Direct comparison with inva-
ive angiography yielded a sensitivity and specificity of 97%
or both to detect/exclude graft stenosis/occlusion.
Weustink et al. (34) reported on the diagnostic accuracy
f the newest-generation CT scanners, the dual-source CT.
total of 100 patients were evaluated in a head-to-head
omparison with invasive angiography; 220 stenoses were
etected in 1,489 evaluated segments on angiography. The
ensitivity and specificity of dual-source CT were both 95%.
ardiovascular Magnetic Resonance Imaging (MRI)
meta-analysis in 3,707 symptomatic patients by Nandalur
t al. (35) showed that both exercise and vasodilator stress
RI detects CAD (sensitivity and specificity of 0.83 and
.86, and 0.91 and 0.81, respectively). Interestingly, al-
hough adenosine and dipyridamole are the most common
odalities of stress-induced MRI testing today, dobut- smine stress MRI was equally efficacious in the detection of
cclusive CAD. In a different study, Bodi et al. (36) showed
hat vasodilator-based MRI tests also carry important prog-
ostic information in patients being evaluated for suspected
AD, similar to nuclear-based stress tests. In combination,
hese studies support the use of vasodilator and dobutamine
ased stress MRI to assess CAD.
Contrast-enhanced MRI was used to define the progno-
is of patients with myocardial disease. Valeti et al. (37)
eported that myocardial damage quantified by delayed
nhancement is less in hypertrophic cardiomyopathy pa-
ients treated with septal myectomy than with alcohol
blation, and this could underlie differences in prognosis.
The ability of cardiovascular MRI to characterize both
yocardial and vascular disease processes was illustrated by
wo studies. The first, by Gilson et al. (38), used MRI in an
xperimental model of infarction showing that suppression
f nitric oxide synthase enhanced border zone contractility
nd reduced post-infarct remodeling. These observations
ave important implications for understanding post-infarct
emodeling at a time when stem cell-induced myocardial
egeneration particularly targeted to the infarct border zone
s being attempted. The second study, by Yeon et al. (39),
ombined vascular imaging by MRI and CT to identify
oronary atherosclerotic plaque activity by delayed enhance-
ent of vessel wall in patients with risk factors compared
ith normal control patients. The study provides a glimpse
f the potential future of multimodal imaging to phenotype
uman cardiovascular disease.
agnetic Resonance Perfusion Imaging
lthough CMR myocardial perfusion imaging can diagnose
oronary stenoses, its ability to discriminate the severity of
bstruction remains uncertain. Costa et al. (40) compared
he results of quantitative magnetic resonance perfusion
maging with FFR measurements from intracardiac pressure
ires in 37 patients undergoing cardiac catheterization.
yocardial perfusion reserve (MPR), calculated from the
atio between stress and rest signal intensity curves using
econvolution analysis, was related to an FFR of greater or
ess than 0.75. An MPR cutoff of 2.04 showed a high
ensitivity of approximately 90% with a moderate specificity
f approximately 50% in predicting an FFR of above or
elow 0.75. Thus, these data indicate that magnetic reso-
ance perfusion imaging provides a useful noninvasive tool
or assessing the hemodynamic significance of coronary
tenosis.
uclear Cardiology
n interesting study focused on the prevalence of CAD in
symptomatic patients with atrial fibrillation. Askew et al.
41) evaluated 374 patients with asymptomatic atrial fibril-
ation and 374 matched control patients with myocardial
erfusion SPECT imaging. Abnormal SPECT studies were
bserved in 52% and 48%, respectively, suggesting a sub-
tantial relation between atrial fibrillation and CAD.
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Highlights From JACC 2007 January 29, 2008:490–512Another study evaluated the relative merits of calcium
coring and SPECT perfusion imaging for assessing long-
erm prognosis in 1,153 patients over a mean follow-up of
2  16 months (42). The main finding was that patients
ithout ischemia had an excellent prognosis, independent
f the calcium score.
ositron Emission Tomography (PET)
ositron emission tomography remains one of the most
mportant tools for probing human disease processes, and
everal publications in the Journal this year are good exam-
les of such power. A study by Tahara et al. (43) showed
hat vascular inflammation is clearly associated with the
etabolic syndrome by imaging carotid arteries with 18F-
uorodeoxyglucose (FDG). Vascular inflammation defined
y PET was associated with waist circumference, hyperten-
ive medication, carotid thickness, high-density lipoprotein
holesterol, insulin resistance, and C-reactive protein
CRP). This study is valuable for understanding how
etabolic syndrome patients become vulnerable to events at
he vascular level.
There is increasing interest in combined PET-CT scan-
ers; Sampson et al. (44) used the CT component to
erform attenuation correction of PET perfusion images
btained with rubidium-82. In a direct comparison with
ngiography, the sensitivity and specificity of this approach
ere 93% and 83%, respectively, to diagnose CAD.
Although PET identification of viable myocardium is
ften utilized in deciding to revascularize patients with
evere LV dysfunction and CAD, evidence that such deci-
ions alter clinical outcome is lacking. Therefore, Beanlands
t al. (45) conducted the PARR-2 (PET and Recovery
ollowing Revascularization) study to assess the effectiveness
f FDG-PET to assist in the management of these patients.
atients with severe LV dysfunction being considered for
evascularization or transplantation were initially stratified
ccording to recent angiography and then randomized to
anagement assisted by FDG-PET (2,018 patients) or
tandard care (2,012 patients). The primary outcome was
omposed of cardiac death, MI, or recurrent hospitalization
ithin 1 year. The percent of patients experiencing the
rimary end point was similar in the 2 arms: 30% in the
ET arm and 36% in the standard arm. However, 25% of
he patients with PET indications for revascularization did
ot have the procedure performed. The hazard ratio for the
omposite outcome in patients who adhered to PET rec-
mmendations was 0.62, p  0.02. Thus, the study did not
rovide evidence that PET-assisted management altered
utcomes in this clinical setting, although those patients
reated according to PET recommendations did seem to
ave superior outcomes.
chocardiography
xercise echocardiography. It has been shown that echo-
ardiography and radionuclide myocardial perfusion im- bging (MPI) have equivalent accuracy in diagnosing
AD. However, the prognostic significance of the mo-
alities remains uncertain. Metz et al. (46) compared the
rognostic value of a normal exercise myocardial perfu-
ion study to a normal exercise echocardiograph in a
eta-analysis. They found that the negative predictive
alue for MI and cardiac death was 98.8% for MPI and
8.8% for echocardiography, and was similar for women
nd men. These data establish that both MPI and
xercise echocardiography have a high negative predictive
alue for cardiac events.
Park et al. (47) reported on improved diagnostic accuracy
f exercise echocardiography when imaging was included
uring as well as after exercise. The exercise echocardiog-
aphy protocol in 104 patients consisted of baseline images,
ollowed by image acquisition at 25 W, 50 W, and peak
xercise. Inclusion of these intermediate stages improved
he sensitivity for CAD (94% vs. 74%, p  0.05); specific-
ties were similar.
Vartdal et al. (48) used strain imaging in patients with
cute infarction; global LV longitudinal strain was assessed
mmediately after reperfusion and was shown to relate well
o infarct size assessed by contrast-enhanced MRI 9 months
ater (r  0.77, p  0.001).
yssynchrony by echocardiography. The role of dyssyn-
hrony as detected by echocardiography in HF patients and
n the decision for resynchronization therapy continued to
e a topic of high interest. Left ventricular dyssynchrony
as found to predict subsequent LV modeling after acute
I. In a study by Mollema et al. (49), 176 patients with
cute MI underwent assessment of synchrony by tissue
oppler recordings within 48 h of intervention. Multivari-
nt analysis showed that LV dyssynchrony was superior in
redicting LV remodeling to other echocardiographic in-
exes such as wall motion score and E/E’. Therefore, LV
yssynchrony can be of value in predicting 6-month remod-
ling in patients with acute MI.
Yu et al. (50) studied the potential role of diastolic
yssynchrony in HF. They performed tissue Doppler re-
ordings in 373 patients, 92 with diastolic HF, and assessed
ystolic and diastolic synchrony as the time to peak myo-
ardial systolic and early diastolic velocities, respectively,
sing a 12-segment model. Time to peak systolic and
iastolic velocity was prolonged in the HF patients. Patients
ith diastolic HF had comparable diastolic dyssynchrony
36%) but less systolic dyssynchrony (39%) than patients
ith systolic HF. Thus, the investigators concluded that
oth diastolic and systolic dyssynchrony were common in
atients with diastolic HF despite the presence of a narrow
RS complex, but were not related to myocardial systolic or
iastolic function. In the same issue, Wang (51) reported a
imilar prevalence of diastolic and systolic dyssynchrony in
atients with diastolic and systolic HF. Interestingly, in this
tudy one-third of patients with diastolic HF had systolic
yssynchrony. It is clear that dyssynchrony is increasingly
eing found wherever it is sought by echocardiography,
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verdiagnosis.
Although the significance of dyssynchrony remains un-
ertain, its response to medical therapy is even less defined.
akemoto et al. (52) performed standard and stain echo-
ardiography in 25 patients with idiopathic dilated cardio-
yopathy before and after treatment with carvedilol. They
bserved a marked improvement of both contractile func-
ion and dyssynchrony in HF patients with a normal QRS
omplex. Thus, it seems that mechanical dyssynchrony can
e ameliorated by effective medical therapy of HF.
Echocardiographic detection of dyssynchrony has thus far
een imperfect in identifying patients with a favorable
esponse to cardiac resynchronization therapy (CRT).
herefore, Gorcsan et al. (53) tested the hypothesis that a
ombined evaluation of longitudinal dyssynchrony by tissue
oppler and radial desynchronization by speckle tracking
ould provide a more accurate assessment of the potential
or a favorable response. In 166 patients they showed that
hen both longitudinal dyssynchrony and radial dyssyn-
hrony were positive, 95% of patients had an increase in
jection fraction.
iastolic dysfunction. Diastolic dysfunction is more prop-
rly termed heart failure with preserved (or normal) systolic
unction (HFNSF). Persson et al. (54) reported a substudy
rom the CHARM (Candesartan in Heart Failure) trial that
ested the hypothesis that diastolic dysfunction was an
mportant predictor of cardiovascular mortality in HFNSF
atients. Diastolic dysfunction, identified on Doppler echo-
ardiographic recordings or elevation determination of
lasma NT-pro-brain natriuretic peptide, were assessed in
12 patients with an average ejection fraction of 50%.
chocardiographic evidence of diastolic dysfunction was
resent in 67% of patients, and moderate or severe diastolic
ysfunction predicted a poor outcome (primary end point
8% vs. 5%, p  0.01). This study was significant in
howing that objective echocardiographic evidence of dia-
tolic dysfunction carries a poor prognostic significance in
atients with HFNSF. In another study, Melenovsky et al.
55) compared the cardiovascular features of patients with
FNSF with individuals with hypertensive LV hypertrophy
nd control patients. They observed that many cardiovas-
ular characteristics were similar in the 2 patient groups.
owever, the HFNSF group had a greater concentric LV
ypertrophy, higher estimated pulmonary artery wedge
ressure, and greater degree of left atrial dilatation and
ysfunction. The investigators concluded that the accentu-
ted LV hypertrophy and left atrial dilation/failure may help
larify the pathophysiology and help identify those at risk
or HF in patients with LV hypertrophy.
ypertrophic cardiomyopathy (HCM). Hypertrophic
ardiomyopathy is classically associated with mildly im-
aired diastolic filling dynamics. However, Kubo et al. (56)
escribed a group of patients in whom no or minimal (15
m) LV hypertrophy and severe restrictive diastolic fillingbnormalities were observed in the setting of HCM. That 8hese patients were part of the spectrum of HCM is
videnced by the facts that they had a family history of
CM, typical histology of the disorder at necropsy, and a
utation in the beta-myosin heavy chain or cardiac tropo-
in I. The restrictive phenotype was observed in 1.5% of
ypertrophic individuals from 2.3% of the families studied,
nd was associated with a poor 5-year rate of survival,
ardiac transplantation, or use of implantable cardioverter-
efibrillator (ICD).
Alcohol septal ablation provides an alternate therapy to
urgical myectomy for patients with HCM, but it remains
nknown whether surgical procedures can effectively be
erformed after a failed attempt at alcohol ablation. Nagueh
t al. (57) reported the results of surgical myectomy in 20
atients who had failed alcohol septal ablation. There was
o operative mortality, and a significant improvement was
bserved in New York Heart Association functional class
ith exercise duration increasing from 168 to 423 s and LV
utflow track.
VUS. Intravascular ultrasound has been used to answer
any questions regarding the pathophysiology of coronary
therosclerosis. Nicholls et al. (58) applied IVUS to deter-
ine the ability of coronary atheromas to regress under
ggressive lipid-lowering therapy with statins. The ability of
esions with a high calcium index to regress was markedly
iminished. A lesser calcium index in a stenosis was asso-
iated with a higher rate of patients showing a change in
theroma burden of at least 5% compared with highly
alcified lesions (70% vs. 53%, p  0.001).
alvular Heart Disease
tatins and aortic stenosis. Changes in the aortic valve in
atients with aortic stenosis are similar to atherosclerosis
nd may therefore be responsive to treatment with statins.
o test this hypothesis, Moura et al. (59) conducted the
AAVE (Rosuvastatin Affecting Aortic Valve Endothe-
ium) study. They randomized 121 consecutive patients to
reatment with rosuvastatin (20 mg/day) or no treatment.
ver the average course of 73 weeks of follow-up, the
eduction in valve area in the rosuvastatin group of 0.05 cm2
er year was significantly less than the change in the control
roup at 0.10 cm2 per year (p  0.004). Thus, these data
rovide evidence that statin therapy may slow the progres-
ion of aortic stenosis. The beneficial effects in the RAAVE
tudy, which were not observed in the SALTIRE (Scottish
ortic Stenosis and Lipid Lowering Trial, impact on
egression), were likely related the fact that patients in the
ALTIRE study were excluded if they had an indication for
tatin therapy, whereas patients in the RAAVE trial were
pecifically put on rosuvastatin if they had elevated lipid
evels. With regard to the treatment of aortic stenosis,
rube et al. (60) reported the results achieved with second-
eneration and third-generation self-expanding percutane-
us aortic valve prostheses. Procedures were performed in
6 patients with severe high-risk aortic stenosis, with acute
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radient from 43 to 9 mm Hg without a change in aortic
egurgitant grade. Procedural mortality was 6%, and overall
0-day mortality was 12%. The combined rate of death,
troke, and MI was 22%. These data indicate that although
ercutaneous aortic valve prostheses are associated with a
igh complication rate, they provide a viable alternative for
igh-risk patients with aortic stenosis who are extremely
igh risk for surgery.
A paper from the Cardiovascular Healthy Study by
ovaro et al. (61) examined the role of inflammation as
epresented by levels of CRP in the progression of aortic
tenosis. They assessed the progression of aortic stenosis by
chocardiography in 5,621 patients, and found a progression
o aortic stenosis during 5 years in 9% of the 1,610 subjects
ith aortic sclerosis. C-reactive protein was associated with
either baseline nor progression to aortic stenosis. Thus,
his study did not provide evidence that inflammation, at
east as represented by CRP, played a major role in the
rogression of aortic sclerosis to aortic stenosis.
It remains unresolved whether mitral valve annuloplasty
s of value in patients undergoing bypass graft surgery for
AD in whom at least moderate to severe functional mitral
egurgitation is present. Milhaljevic et al. (62) performed a
etrospective analysis of 390 such patients, in 290 of whom
itral annuloplasty was performed. Groups were propensity
atched. No difference in 1-, 5-, or 10-year survival was
bserved despite the fact that patients undergoing bypass
urgery alone were more likely to have a moderate to severe
ost-operative mitral regurgitation. Functional class im-
roved in both groups. Although this study has all the
imitations of a retrospective analysis, it did provide evidence
hat mitral valve annuloplasty in addition to bypass surgery
oes not enhance functional status or prolong survival in
atients with moderate to severe mitral regurgitation.
iomarkers
cute coronary syndromes (ACS). Myeloperoxidase
MPO) is a neutrophil and monocyte enzyme that amplifies
he reactivity of hydrogen peroxide through generation of
ypochlorous acid, free radicals, and reactive nitrogen spe-
ies. Mocatta et al. (63) provided possible new mechanistic
nd clinical data regarding MPO in ACS. They followed up
12 patients with MI for 5 years and observed a 1.8-fold
reater adjusted risk of death in patients with plasma MPO
55 g/ml.
Monocyte chemoattractant protein (MCP)-1 is a chemo-
ine recruiting signal for monocytes that may function as
oth a mediator and a biomarker of ACS. de Lemos et al.
64) measured MCP-1 at baseline, 4 months, and 12
onths after early stabilized ACS and correlated levels with
linical events in the Z phase of the A to Z (Aggrastat to
ocor) trial. They found that higher MCP-1 levels weressociated with an increased risk for long-term death and pajor adverse cardiac outcomes, independent of low-density
ipoprotein (LDL), CRP, and brain natriuretic peptide.
Heart-type fatty acid binding protein (H-FABP) is
eleased into the circulation after myocardial ischemia and
ecrosis and thus may be of value in the setting of ACS. To
his end, Kilcullen et al. (65) examined H-FABP within 12
o 24 h after symptoms of ACS. Heart-type fatty acid
inding protein proved to be a powerful predictor of death,
ven when troponin levels were normal.
Liuzzo et al. (66) studied whether the expansion of
nusual T lymphocytes, CD4 CD28null cells, might rep-
esent a key pathogenetic mechanism of recurrent plaque
nstability. They examined T cells in patients with unstable
ngina grouped according to occurrence of prior and sub-
equent events. CD28null cells were independent predictors
f future acute coronary events (odds ratio 3.1).
eart failure (HF). Growth differentiation factor
GDF)-15 is a stress-responsive member of the transform-
ng growth factor beta cytokine superfamily. Kempf et al.
67) measured circulating levels of GDF-15 in 455 patients
ith CHF and low ejection fraction. Growth differentiation
actor-15 was closely correlated to New York Heart Asso-
iation functional classification and showed that the risk of
eath at 48 months increased with increasing quartiles (56%
ortality in highest quartile) independent of established
iomarkers such as NT-pro-brain natriuretic peptide.
F
ltrafiltration. Costanzo et al. (68) studied intravenous
iuretics versus ultrafiltration for patients with decompen-
ated HF in the UNLOAD (Ultrafiltration Versus Intrave-
ous Diuretics for Patients Hospitalized for Acute Decom-
ensated Heart Failure) trial. Patients hospitalized for acute
F and hypervolemia were randomized to ultrafiltration or
arenteral diuretics. Primary end points were weight loss
nd dyspnea assessment at 48 h. Ultrafiltration safely
roduced greater fluid and weight loss than diuretics, with
o effect on dyspnea, and reduced resource use for HF at 90
ays.
Cassar et al. (69) compared outcomes of patients treated
or obstructive sleep apnea (OSA) versus patients with
ntreated OSA, all of whom had undergone PCI. The
nvestigators concluded that treatment of OSA in patients
ho then underwent PCI resulted in a significant reduction
n cardiac death but not in MACE or major adverse
ardiovascular or cerebral events when compared with un-
reated OSA patients. They suggest that screening for and
reating OSA in patients with CAD undergoing PCI may
esult in decreased cardiac death and overall mortality.
A problem in treating patients with advanced HF is that
ntravenous loop diuretics may produce worsening renal
unction or induce resistance. Therefore, Givertz et al. (70)
ested a new adenosine A1-receptor antagonist in regard to
ts ability to produce diuresis and preserve renal function in
atients with acute decompensated HF and renal impair-
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January 29, 2008:490–512 Highlights From JACC 2007ent or diuretic resistance. In 146 patients with acute
ecompensated HF, the new agent (KW-3902, rolofylline)
ncreased urine output during 4 days and decreased the dose
f furosemide administered. A single infusion of 10, 30, or
0 mg KW-3902 increased hourly urine output and esti-
ated creatinine clearance with a peak affect at 24 h. Thus,
denosine A-1 receptor antagonism provides an effective
eans of inducing diuresis in patients in whom acute
ecompensated HF is complicated by renal impairment or
iuretic resistance.
Considerable controversy has surrounded the use of
ecombinant human B-type naturiuretic peptide (nesiritide)
n the treatment of HF, particularly with regard to its ability
o compromise renal dysfunction. Therefore, Mentzer et al.
71) conducted the NAPA (Nesiritide Administered Peri-
nesthesia in patients undergoing cardiac surgery) trial to
xamine the effects of this agent on post-operative renal
unction, clinical outcomes, and safety in patients undergo-
ng coronary bypass. Compared with placebo, nesiritide was
ssociated with an attenuation of the increase in serum
reatinine (0.15 vs. 0.34, p  0.001), a smaller decrease in
lomerular filtration rate (10.8 vs. 17.2, p  0.001), and a
reater urine output during the initial 24 h after surgery.
he study group was relatively small, and the use of other
edications was not controlled, but the current study
rovides some reassurance regarding the use of the agent in
his clinical setting.
Another study directed to assess the effect of nesiritide on
enal function was performed by Witteles et al. (72) in
atients with acute decompensated HF and pre-existing
enal dysfunction. This randomized, double-blind, placebo-
ontrolled clinical trial assigned 39 patients to nesiritide and
6 to placebo; serum creatine was 1.82 mg per dl/mg and
.86 mg per dl/mg respectively. No significant differences
ere observed in the incidence of a 20% creatine increase, or
n the change in serum creatine. Secondary end points also
ere similar. These findings mute, but do not resolve,
oncerns regarding the ability of natriuretic peptides to
roduce renal insufficiency in acute HF patients.
An important study reported improved survival in pa-
ients with end-stage HF who were currently listed for heart
ransplantation. Lietz et al. (73) examined records from the
nited Network for Organ Sharing for nearly 40,000 status
and status 2 and 3 patients awaiting transplantation. The
nvestigators observed that the 1-year survival on the heart
ransplant waiting list improved from 49% to 69% for status
and from 81% to 89% for status 2 candidates between the
ears 1990 to 1994 and 2000 to 2005. The investigators
bserved that because the 1-year survival of status 2 candi-
ates awaiting heart transplantation approaches that of
ransplantation itself, early listing of status 2 patients may be
f little value. In an accompanying editorial, Young (74)
uestioned whether or not the time had come to perform a
andomized clinical trial evaluating the benefit of cardiac
ransplantation in stable outpatients with chronic HF
United Network for Organ Sharing status 2). cIt is clear that the majority of patients in whom an ICD
s placed will never require its use, raising the question of
hether we can predict which patients are most likely to
enefit from ICD implantation. To address this, Golden-
erg et al. (75) performed a post-hoc analysis of MADIT-II
Multicenter Automatic Defibrillator Implantation Trial II)
o determine the relationship among blood pressure, risk of
udden cardiac death, and ICD benefit in patients with
schemic LV dysfunction. Multivariate analysis in the con-
rol arm showed that 10-mm Hg increments in systolic
ressure were associated with 14% and 16% reductions in
he risk of cardiac mortality and sudden death, respectively.
oreover, placement of an ICD provided the least survival
enefit (e.g., hazard ratios [HRs] of 1.04 and 1.05, respec-
ively) to the higher blood pressure quartile of the popula-
ion (systolic pressure 130 mm Hg). These results raise
he possibility that blood pressure measurement may be
seful in identifying lower-risk patients in whom sudden
eath is unlikely to occur.
Low blood pressure has been noted to be an important
isk factor for adverse outcomes in HF, and it often limits
reatment options. A fixed-dose combination of isosorbide
initrate/hydralazine (FDC I/H) improved survival in
-HeFT (African-American Heart Failure Trial). Anand
t al. (76) examined whether blood pressure lowering is
ritical for FDC I/H efficacy and whether low blood
ressure limits the efficacy by looking at treatment effects in
-HeFT patients whose systolic blood pressure was above
r below the median of 126 mm Hg at study entry. Not
urprisingly, patients with lower blood pressures had more
evere HF and higher risk for death or HF hospitalization.
espite the fact that FDC I/H reduced blood pressures in
atients above the median but not in those that were below
he median, treatment had similar effects on mortality and
ospitalization in patients above and below the blood
ressure median. Moreover, FDC I/H did not further lower
ystolic blood pressure even in the lowest quintile group,
hose baseline systolic blood pressure was 100 mm Hg.
hus, presence of low blood pressure should not be consid-
red an absolute contraindication for the use of FDC I/H,
articularly in asymptomatic patients.
Over the past year, several articles published in the
ournal have provided insights into fundamental mecha-
isms and new approaches to prevention and treatment of
ardiac remodeling. Although statins possess properties
eyond their ability to lower lipids and previous studies have
hown favorable effects in HF patients, the mechanism(s)
esponsible have not been well defined. Zaca et al. (77)
tudied the effects of low-dose (LD; 0.5 mg/kg daily) and
igh-dose (HD; 3.0 mg/kg daily) rosuvastatin on the
rogression of LV dysfunction and remodeling in dogs with
F induced by coronary microembolization. Although
here was no significant effect of LD rosuvastatin on LV
olumes or function, treatment with HD significantly at-
enuated changes in LV volumes and ejection fraction
ompared to control. Moreover, HD but not LD rosuvas-
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umor necrosis factor (TNF)- and significantly increased
he number of circulating bone marrow-derived stem cells.
hese results support the possibility that statins may im-
rove outcomes in HF patients by mechanisms that tran-
cend their ability to lower lipids.
Early post-MI activation of the sympathetic nervous
ystem has been associated with the development of remod-
ling. Kasama et al. (78) compared the effects of 48-h
nfusion of isosorbide dinitrate (ISDN) or atrial natriuretic
eptide (ANP) on cardiac sympathetic nerve activity
CSNA) and remodeling parameters in 50 patients with first
nterior acute MI after primary angioplasty. Despite similar
isk factors and extent of initial damage, patients treated
ith ANP showed reduced total defect score and 123I-meta-
odobenzylquanidine uptake (as an indicator of norepineph-
ine uptake) at 3 weeks post-MI and significantly lower
DV and higher EF. These findings raise the intriguing
ossibility that prophylactic treatment with ANP early in
he post-MI period might be an effective way of inhibiting
he sympathetic nervous system in the heart, which then
ranslates into favorable effects on subsequent post-MI
ardiac remodeling.
Although aldosterone receptor antagonists improve sur-
ival in patients with post-MI LV dysfunction and HF,
heir ability to favorably affect the remodeling process has
ot been fully established. Chan et al. (79) randomized 51
atients to either the angiotensin receptor blocker (ARB)
andesartan or combination of an ARB and spironolactone.
everse remodeling was assessed serially over 1 year by MRI
nd tissue Doppler imaging. Compared with the ARB
lone, combination therapy reduced EDV, end-systolic
olume, and LV mass index, and significantly increased
eak basal systolic velocity and strain by tissue Doppler
maging.
Klotz et al. (80) hypothesized that angiotensin-
onverting enzyme inhibition (ACE-I) during LV assist
evice (LVAD) support in patients with end-stage HF
ould prevent potentially deleterious effects on the extracel-
ular matrix. To study this, they obtained heart samples
efore and after LVAD implantation in 7 patients who
eceived and 15 patients who did not receive ACE-I while
eing maintained on an LVAD. They found that Angio-
ensin II was reduced in the ACE-I group but increased in
ontrol subjects and that cross-linked collagen decreased
uring LVAD support in the ACE-I group. Moreover, LV
ass and myocardial stiffness were lower in the ACE-I
roup, and LV and right ventricular (RV) matrix metallo-
roteinase-1/tissue inhibitor of metalloproteinase-1 ratio
ere normalized. Because increased fibrosis and LV stiffness
ave been demonstrated after LVAD placement, these
esults raise the possibility that ACE-I might prevent these
hanges and improve the likelihood of recovery of cardiac
unction.
There has been considerable controversy regarding the
hiazolidinediones (TZDs) and their impact on cardiovas- eular disease. Dargie et al. (81) studied the effects of
osiglitazone (RSG) in patients with type 2 diabetes and
ild New York Heart Association functional class I to II
hronic HF. The 224 patients in the study were assigned to
eceive RSG in addition to other antidiabetic therapies.
fter 52 weeks, changes in LVEF were similar between the
roups and patients receiving RSG had better glycemic
ontrol. Although new or worsening edema and increased
F medication was more common with RSG treatment,
here were no differences in other adjudicated end points
nd withdrawal for adverse events was equal between
roups. These findings were similar to those of a retrospec-
ive survey done by Aguilar et al. (82) of a national cohort of
eterans with HF and diabetes. In this ambulatory popula-
ion, the use of TZDs was not associated with an increased
isk of HF hospitalization or total mortality.
oronary Disease and Atherosclerosis
ontroversies in cardiology. Two major issues generated
onsiderable controversy during the past year and received
n-depth analysis in the pages of the Journal. The first is the
ontinued debate regarding the potential risk of stent
hrombosis related to DES. Kaul et al. (83) reviewed the
linical data and emphasized that off-label use of DES may
e responsible for late stent thrombosis events and advo-
ated stricter adherence to evidence-based medicine and
n-label use of therapies. Holmes et al. (84), in contrast,
rofessed a more optimistic view of DES, emphasizing the
ack of a mortality difference to BMS. All agreed to the need
or further research.
Controversy regarding the role of interventional cardiol-
gy in clinical practice was heightened after the publication
f the COURAGE (Clinical Outcomes Utilizing Revascu-
arization and Aggressive Drug Evaluation) trial (85), a
tudy comparing intensive medical therapy plus PCI to
ntensive medical therapy alone in patients with stable
oronary disease. The trial’s main conclusion was that there
as no advantage to an initial strategy of PCI over intensive
edical therapy alone. A critique of the COURAGE trial
y Kereiakes et al. (86) emphasized the better angina-free
tatus in the PCI group without additional mortality and
urther claimed that potential benefits of DES and more
omplete revascularization may further improve outcomes
ith the PCI approach. A spirited defense of the trial by
iamond and Kaul (87) emphasized the novel information
n the trial and that indeed medical treatment is the
referred initial approach in stable CAD, with potential
ignificant savings for the health care system.
ngina pectoris. One of the consequences of the COUR-
GE trial has been a renewed interest in new medical
herapies for ischemic heart disease. Tolerance to nitroglyc-
rine has been shown to be associated with free radical
roduction and endothelial dysfunction; whether a similar
henomenon exists for isosorbide-5-mononitrate has hith-
rto been unknown. Thomas et al. (88) studied the effect of
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January 29, 2008:490–512 Highlights From JACC 200720 mg isosorbide-5-mononitrate in 19 healthy subjects and
howed that indeed the same phenomenon exists for this
orm of nitrate and that the endothelial dysfunction is
eversed by co-infusion of vitamin C into the artery,
lluding to an oxidative mechanism. These findings raise
oncerns regarding the impact of these medications on
ong-term vascular health (89). Novel antianginal drugs are
herefore needed. The safety of one novel medication for
ngina, ranolazine, was evaluated in the ROLE (Ranolazine
pen Label Experience) study (90). Over a mean follow-up
f close to 3 years, there was no evidence of increased
ortality and no episodes of torsades de pointes, despite a
rolongation in mean QTc of 2.4 s.
latelets and antiplatelet therapy. The central role of the
latelet in acute coronary syndromes and in the complica-
ions of percutaneous interventions continued to be a focus
f intense research in 2007. The Journal in 2007 published
everal key studies that addressed the role of platelet
ctivation in high-risk groups such as diabetic patients (91),
nd the role of resistance to antiplatelet agents, particularly
he thienopyridines. New data were also presented on
merging antiplatelet agents.
The role of persistent platelet aggregation despite dual
ntiplatelet therapy (aspirin and clopidogrel) in post-
tenting ischemic events was studied by Bliden et al. (92) in
group of 100 patients undergoing elective PCI. The
nvestigators found that increased platelet aggregation pre-
tenting, measured either by adenosine diphosphate (ADP)-
nduced platelet aggregation or by thromboelastography
redicted ischemic complications. Assessment of residual
latelet function may therefore be useful in targeting pa-
ients needing additional antiplatelet therapy, whether it is a
igher dose of clopidogrel or a IIb/IIIa inhibitor. In the
ame study the investigators showed that addition of the
Ib/IIIa inhibitor eptifibatide significantly further inhibited
latelet aggregation in those patients with residual activity.
The importance of atorvastatin–clopidogrel interaction
which had previously attracted considerable attention given
he wide use of atorvastatin in patients with coronary
isease) was discounted in a retrospective analysis of the
HARISMA (Clopidogrel for High Atherothrombotic
isk, Ischemic Stabilization, Management, and Avoidance)
rial (93). The lack of prospective data, however, particularly
n subgroups with heightened platelet activation, empha-
izes the need for further study of drug–drug interactions
123).
Various approaches have been taken to address the
esidual risk with dual antiplatelet therapy. Since clopi-
ogrel is a pro-drug requiring activation by CYP3A4, a
igher loading dose of 600 mg has been widely adopted.
owever, some patients still show nonresponsiveness. In an
bservational study with a total of 804 patients undergoing
ES implantation, Buonamici et al. (94) demonstrated
onresponsiveness, even with the 600-mg loading dose, is
ssociated with a 3-fold increased risk of stent thrombosis.
hus, clopidogrel nonresponsiveness is therefore not simply plaboratory curiosity, but an important clinical entity. Is
onresponsiveness a class effect or specific to one agent or
nother? In a crossover study, Campo et al. (95) showed that
onresponsiveness to either ticlopidine or clopidogrel was
ommon, occurring in 1 of 5 patients, but that nonre-
ponsiveness to both drugs occurred in only 3.5%, indi-
ating that drug-specific mechanisms were more impor-
ant. Newer agents may also lead to further therapeutic
ptions. These include prasugrel as well as AZD6140, a
eversible oral ADP antagonist, with encouraging results
n the DISPERSE-2 (Dose Confirmation Study assessing
nti-Platelet Effects of AZD6140 vs. clopidogRel in non–
T-segment Elevation myocardial infarction) study (96,97)
ublished in the Journal this year.
dvances in antithrombotic therapy. Fondaparinux is a
ynthetic factor Xa inhibitor, which was compared with
noxaparin in the OASIS-5 (Fifth Organization to Assess
trategies in Ischemic Syndromes) study in patients under-
oing PCI (98). The results confirmed the net clinical
enefit of fondaparinux showing similar ischemic events but
lesser bleeding rate. Angiographic complications with
ondaparinux (an increased risk of catheter thrombosis)
ere managed by an additional bolus of unfractionated
eparin during the procedure.
I. Despite recent advances, the mortality of patients with
ardiogenic shock remains high. But what is the prognosis
n those who survive the initial hospitalization? Data from
he GUSTO-I (Global Utilization of Streptokinase and
PA for Ocluded Arteries-I) (99) trial showed that in those
ho survived 30 days, annual mortality was 2% to 4%,
imilar to nonshock patients. Thus, there is a need to
mprove the immediate therapy of patients with cardiogenic
hock to improve short-term mortality. One group of
atients who are at increased risk of developing shock are
hose in whom fibrinolytic therapy has failed. A therapeutic
ption for these patients is rescue angioplasty versus repeat
brinolysis. Which therapy is preferable was the subject of a
eta-analysis published in the Journal (100). The analysis
dentified rescue PCI as having improved outcomes with no
enefit for repeat fibrinolytic therapy and potentially in-
reased harm.
besity, the metabolic syndrome, and cardiovascular
isease. The obesity epidemic prompted multiple studies
n the effect of obesity and the related metabolic syndrome
n cardiovascular disease. Gami et al. (101) performed a
ystematic review and meta-analysis of longitudinal studies
f obesity and showed an increased risk (risk ratio of 1.78)
or cardiovascular events and death, with an even higher risk
n women. Obesity was also linked with incident atrial
brillation (102) in those age 65 or less in a retrospective
tudy from Olmsted County, as was the related entity of
bstructive sleep apnea.
The impact of the metabolic syndrome extends to inter-
entions such as coronary artery bypass grafting (CABG).
n a large retrospective study (103) of 5,304 consecutive
atients undergoing CABG surgery, the relative risk of
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Highlights From JACC 2007 January 29, 2008:490–512ortality was increased 3-fold in patients with the meta-
olic syndrome. The investigators hypothesized that the
ro-inflammatory and pro-thrombotic milieu of the meta-
olic syndrome may be contributing to the increased mor-
ality. Indeed the relationship between the metabolic syn-
rome and inflammation has now been confirmed not only
n a Western population, but also in a large study from
hina (104), in which CRP was strongly associated with
besity and the metabolic syndrome.
What are the best measurements for overweight and
besity in predicting cardiovascular risk? Data from the
allas Heart Study (105) assessed prevalent atherosclerosis
ith coronary artery calcium score. Waist–hip ratio rather
han body mass index or waist circumference was found to
e the better predictor.
The obesity epidemic is also affecting children and
dolescents, but the criteria for metabolic syndrome have
een developed in adults. An important step forward was
ublished by Jolliffe and Janssen (106), who utilized growth
urve modeling for each component of the metabolic
yndrome. Using their derived age-specific definitions, the
revalence of metabolic syndrome in adolescents doubled
ver the last decade to about 1 in 10 adolescents.
What is the influence of specific dietary components on
ardiovascular risk? Particular interest has been focused on
he influence of refined carbohydrates and foods with high
lycemic load and glycemic index. In a population-based
tudy, Beulens et al. (107) showed an association between
igh dietary glycemic load and glycemic index with in-
reased cardiovascular risk, particularly in obese women.
holesterol, statins, and pleiotropism. Over the past few
ears various studies have emphasized non-LDL factors for
therosclerosis, such as the independent influence of inflam-
ation (most often reflected in high-sensitivity CRP levels)
nd the role of particle size (dense LDL vs. buoyant or fluffy
DL). A series of articles in the Journal during the past year
llowed us to put these divergent emphases in perspective.
El Harchoui et al. (108) examined the relationship
etween atherosclerosis and LDL particle size and number
n the EPIC (Evaluation of c7E3 for the Prevention of
schemic Complications)-Norfolk Prospective Population
tudy. Although LDL particle number and size were
redictive in univariate analysis, their additive value was lost
fter adjusting for triglycerides and high-density lipoprotein
holesterol. Similarly, a meta-analysis by Kinlay (109)
howed that changes in CRP were primarily related to the
agnitude of change in LDL, and that non-LDL effects of
tatins on inflammation are of much smaller magnitude.
These findings reinforce the National Cholesterol Edu-
ation Program guidelines emphasizing LDL-C as the
rimary target of therapy, particularly in the stable outpa-
ient setting. In the acute setting, statins may still have
mportant pleiotropic effects as shown in the ARMYDA-
CS (Atorvastatin for Reduction of Myocardial Damage
uring Angioplasty-Acute Coronary Syndromes) trial110). In 171 patients with non–ST-elevation acute coro- aary syndrome (NSTE-ACS), 80 mg atorvastatin before
CI and an additional 40 mg after PCI resulted in a marked
eduction in procedure-related and 30-day MACE.
Traditionally risk assessment for coronary disease is
arried out in middle age. However, cholesterol levels vary
uring life. Are levels measured earlier in life predictive of
ubsequent risk? The CARDIA (Coronary Artery Risk
evelopment in Young Adults) study (111) examined the
redictive value of early adult cholesterol level on coronary
alcification measured 15 years later. Surprisingly levels
easured in early adulthood predicted subsequent coronary
alcification and were equally or more informative than
evels measured later in life. These provocative findings
rgue for earlier risk assessment.
Given the large portion of the population that is eligible
or cholesterol-lowering therapy, especially if started at a
ounger age, the safety of statin therapy is of great interest.
n one of the most provocative articles of the year, data from
arge randomized statin trials were evaluated for the rela-
ionship between the magnitude of lipid lowering and the
isk of liver function test abnormalities, rhabdomyolysis, and
ancer (112). Surprisingly, the investigators found a corre-
ation between lower achieved LDL levels and increased
ancer risk. In an accompanying editorial (113), it was
mphasized that these findings are hypothesis generating
nd do not change the overall risk–benefit ratio in patients
ho are at high risk for coronary disease.
pidemiology. Ford and Capewell (114) investigated cor-
nary artery disease (CAD) mortality rates from 1980 to
002 using data from the U.S. Centers for Disease Control
nd Prevention and population counts from the U.S. Cen-
us. They concluded that although the overall CAD death
ate has declined substantially during this period, among
ounger adults (ages 35 to 54 years) the decline in the CAD
eath rate has stabilized or even slightly increased in recent
ears. They also noted that these recent unfavorable trends
n CAD mortality have coincided with substantial deterio-
ation in several risk factors for CAD (obesity, diabetes, and
ypertension) in this population of younger adults.
ongenital Heart Disease
asic science insights. Hinton et al. (115) did a 3-generation
amily history and sequential sampling of 235 family mem-
ers found after identifying 38 probands with hypoplastic
eft heart syndrome (HLHS). They concluded that HLHS
as almost exclusively the result of a genetic cause. Fifty-
ve percent of the families had more than 1 affected
ember. Eleven percent of the probands who had aortic
nd mitral hypoplasia also had pulmonary and tricuspid
alve abnormalities—most dysplasia. Among the 21 affected
amilies, cardiovascular abnormalities were documented in
1 of the 51 siblings and 23 of 106 first-degree relatives,
ost commonly bicuspid aortic valve (10%), hypoplastic left
eart, and aortic root dilation with aortic coarctation. There
re factors that determine why left-sided gene defects in
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January 29, 2008:490–512 Highlights From JACC 2007enetically predisposed individuals end up with relatively
ild abnormalities such as bicuspid aortic valve or the full
orm of HLHS. The implications for genetic counseling
nd the impetus for further family studies of left-sided heart
efects are both among the most important aspects of this
aper in the Journal.
Levy et al. (116) sought to evaluate the histologic basis of
rreversible pulmonary hypertension in the clinical setting of
ongenital heart disease patients in whom Eisenmenger
yndrome develops. This small but important study looked
t antiapoptotic and pro-apoptotic markers in vascular and
erivascular cells in lung biopsy samples from 18 patients, 7
ith reversible and 11 with irreversible pulmonary hyper-
ension, as well as 6 control patients. The antiapoptotic
rotein Bcl-2 was highly expressed by pulmonary endothe-
ial cells in all cases of irreversible pulmonary hypertension,
ut in none of the reversible cases or control patients.
ntimal proliferation was present in 10 of the 11 irreversible
ulmonary hypertension patients, but never in the reversible
ases. Similarly, perivascular inflammatory B cells expressed
ore antiapoptotic proteins in the irreversible cases than in
he reversible. The reversible patients also had regulation of
ndothelial nitric oxide synthase and new small vessel
ormation at sites of occlusion. The data suggest that the
emodeling process in the course of pulmonary hypertension
aused by congenital heart disease involves an acquired
poptosis-resistant phenotype in endothelial cells, likely to
esult in impaired endothelial apoptosis so as to produce
ntimal proliferation and occlusion of distal vessels. Consis-
ent with this hypothesis, CD34 was found in structures
urrounding all vessels, and vascular endothelial growth
actor (VEGF) and endothelial nitric oxide synthase are
ikely involved in neoangiogenesis. The investigators admit
hat this is only a cross-sectional study with histomorpho-
ogic data and some clinical hemodynamic correlations.
owever, this study highlights the role of impaired endo-
ardial cell apoptosis and inflammatory cell apoptosis in the
athogenesis of irreversible pulmonary hypertension com-
licating congenital heart disease.
ardiac mechanics in congenital heart disease. Pettersen
t al. (117) studied 14 patients post-operatively after atrial
witch for transposition of the great vessels and compared
he contraction pattern of the systemic RV with findings in
he RV and LV of 14 normal subjects using tissue Doppler
maging and MRI. They evaluated RV wall circumferential
train in the short axis and longitudinal strain, and per-
ormed MRI tissue tagging in both experimental and
ontrol patients. They examined circumferential strain at
he midventricular area of the lateral wall as a reference
ethod and measured global, basal, and apical rotation by
RI. Geometric RV diameter was larger than LV diame-
er, as expected, in the Senning patients. The RV free wall
ircumferential strain was greater than longitudinal
train—a finding that is opposite from the normal free wall
nd is similar to the contraction pattern of the normal RV.
train rate also showed greater circumferential than longi- wudinal strain; however, the values were significantly less in
he systemic RV than the normal LV. In contrast to normal
ubjects, global rotation of the systemic RV was essentially
bsent at both apical and ventricular levels. The findings
ocument a shift in the systemic RV free wall from
ongitudinal to circumferential contraction—a finding that
rings it closer to the mechanics of the LV. Inherent torsion
as absent. None of the patients had evidence of HF, so this
ysfunction does not seem to be significant, but likely is an
daptive change to systemic load. As an adaptive response,
he lack of torsion and the reduced strain rate may, however,
mply abnormal function.
ongenital diseases of the aorta. Several articles dealt
ith the aortic valve and the aorta as a system, and the
mplications of altered flow and altered wall structure on the
atural history of LV outflow tract obstruction.
In the first (118), 310 patients with right and left
oronary leaflet and right and noncoronary leaflet fusion
icuspid aortic valve were selected randomly from 1,192
atients followed up for 16 years. A right noncoronary
orphology of fusion was predictive of valve intervention
hen compared with the right–left coronary fusion. In
ongitudinal evaluation of 799 echocardiograms, right non-
usion was also associated with a progressive degree of valve
ysfunction. Right nonfusion patients were more likely to
e male (73 vs. 45), less likely to have associated coarctation
ompared with right–left fusion (41 compared with 5), and
ore likely to have significant aortic stenosis or aortic
egurgitation at first follow-up. The right nonfusion pa-
ients were much more likely to have progression in valve
ysfunction and/or require intervention during childhood
ompared with other morphologic valves.
In the second study, Grotenhuis et al. (119) examined
RI and described reduced aortic elasticity and its associ-
tion with aortic regurgitation and LV hypertrophy in
atients with nonstenotic bicuspid aortic valve. Twenty
ontrol patients and 20 patients with nonstenotic aortic
alve were studied. Distensibility and pulse wave propaga-
ion were evaluated—the latter in the descending aorta.
atients with bicuspid aortic valve had significantly in-
reased pulse wave velocity and diminished distensibility at
he level of the sinotubular junction. Aortic diameter was
ncreased at all 4 levels—dilation was most prominent at the
evel of the sinus of Valsalva. The study showed frequently
educed aortic elasticity and aortic root dilation in the
atients with nonstenotic valves. Reduced aortic wall veloc-
ty was associated with mild aortic regurgitation and LV
ypertrophy even in the patients with relatively normal
unctioning bicuspid aortic valves.
nterventions in congenital heart disease. Butera et al.
120) reported a large single-center experience with the
mplatzer ventricular septal defect (VSD) occluder for
uscular and perimembranous VSD (AGA Medical Corp.,
lymouth, Minnesota). A total of 104 patients underwent
ranscatheter closure—with a median age of 14 years (66
ere 10 years of age), and median weight was 26.5 kg,
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Highlights From JACC 2007 January 29, 2008:490–512ith the smallest being 6.5 kg. The investigators performed
heir studies under transesophageal guidance and crossed
he septum retrograde from the left ventricle. Device sizes
ere 14 to 17 mm. Multiple and surgical residual VSDs
ere called complex procedures. Although no deaths oc-
urred, there were 13 significant complications in 11 pa-
ients including 2 device embolizations. No significant valve
egurgitation occurred. Only trivial VSD prosthetic leak
ccurred. After 3 months, 4 developed complete AV block,
ymptomatic or asymptomatic, best predicted by young age.
ll of the patients in this study received a perimembranous
SD occluder, which is asymmetrical so as to not extend
oward the aortic valve from the perimembranous
mplantation.
Jones et al. (121) reported a 2-year U.S. clinical trial
nvolving 119 nontraining cases treated with the Helex
eptal occluder (Gore Medical, Flagstaff, Arizona) and 128
ith surgical repair of a secundum ASD. Patients in each
roup were followed up at 24 h, 4 weeks, 6 months, and 12
onths. Mean subject age was 12 years in the device group
nd 9 years in the surgical group. Estimated ASD size was
0 mm with the device and 15 mm in the surgical group.
ajor adverse events were reported in 5% of device patients
nd 7% to 10% of surgical patients. Removal of the device
as required in 5 of the 7 patients with adverse events, and
patients had post-procedural device embolization. In the
urgical arm, post-pericardiotomy syndrome occurred in 8
atients, with pericardial tamponade contributing to the
eath of 1. In conclusion, the study overall showed that the
elex septal occluder was a safe and effective alternative to
urgery for secundum ASDs 22 mm balloon occlusion
iameter.
ongenital rhythm abnormalities. A paper by Etheridge
t al. (122) from 3 large centers reviewed the criteria for
iagnosis and treatment strategies for children with long
T syndrome (LQTS).
A total of 128 patients were identified from 91 families,
nd these included 41% probands; 66% of the patients were
emale, and diagnosis was made at an age of 8 years. The
Tc was a mean of 487  39 ms. Genetic testing was done
n 56%, family history having been the most frequent cause
or referral. A KCNQ1 mutation was the most common
efect identified; 98% of the study population was on
eta-blockers, most commonly nadolol. A total of 27
atients had devices placed; 74% had dual-chamber devices.
total of 23 eventually underwent ICD implantation; 63%
f patients had a prolonged pacing episode, with more than
0% of heartbeats paced. Five patients had had at least 1
ppropriate and 4 patients had had at least 1 inappropriate
ischarge.
During a mean follow-up of 3.5 years, 13 patients (48%)
equired reinterventions. Device patients had a longer QT
nterval and were more likely to have symptoms than the
roup treated medically. There were 2 deaths. The investi-
ators summarized that LQTS is being increasingly recog-
ized in the absence of symptoms in conjunction with Tamily history and genetic testing. Many of these patients
re not highly symptomatic and generally do well. In the era
f genetic testing and device implantation, overall mortality
s low. Also, the patients in this group are relatively unlikely
o need ICD implantation as long as there is compliance
ith necessary exercise restriction and adequate response to
eta-blocker therapy.
dult congenital heart disease. The ever-increasing pop-
lation with adult congenital heart disease now presents a
orkforce issue. Guidelines for the treatment of adults with
HD are in the process of being developed by an American
ollege of Cardiology/American Heart Association com-
ined task force. Gurvity et al. (123) looked at the trends in
ospitalization during the transition from adolescence to
dulthood by analyzing data from the California Office of
tatewide Health Planning and Development—a discharge
ataset from 2000 to 2003. The upper age of the sample was
4 years. Admission for a cardiac-related principal proce-
ure was an additional independent variable, as was admis-
ion from an Emergency Department versus a nonemergent
ource. There were 9,017 nonpregnancy-related hospitaliza-
ions in these patients in 368 hospitals in California. Only
% were related to a CHD operation, and operations were
erformed in 70 hospitals. For the patients ages 21 years to
4 years, there were 5,675 discharges from 346 hospitals; of
hese, only 25 hospitals averaged more than 12 discharges
er year, and they accounted for 44.8% of the total number
f discharges. For discharges associated with congenital
eart operations, there were 484 discharges with 67 hospi-
als. Four of the hospitals alone accounted for 41.5% of the
urgical discharges. With increasing age and transition to
dult care, patients were more likely to be hospitalized by
ay of the emergency department into a hospital that did
ot specifically have expertise or a designated adult congen-
tal heart center as part of its profile. Public insurance or
ninsured status also increased the likelihood of admission
hrough the emergency department. Although in the group
nder 21 years age, 70% of procedures were done in
ospitals performing most of the surgeries, in the older age
roup, the most experienced facilities accounted for 45%.
hus, the pattern of hospitalization changes in and around
he transition from adolescence to adulthood, with more use
f hospitals that have fewer congenital heart disease hospi-
alizations and likely less congenital heart experience.
ene therapy. Evidence that gene therapy is not dead was
rovided by Henry et al. (124), who assessed the effects of
uman adenovirus serotype 5 with human FGF-4 gene
nsert (Ad5FGF-4) to increase exertional capacity and
yocardial perfusion in patients with CAD and refractory
ngina. In a pooled data analysis from 2 nearly identical
rials the investigators reported a significant gender-specific
2 females) beneficial effect of Ad5FGF-4 on total exercise
ime, time to 1-mm ST-segment depression, time to an-
ina, and Canadian Cardiovascular Society class in women.
hus, these data indicate that gene therapy for angiogenesis
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January 29, 2008:490–512 Highlights From JACC 2007ay have a potential role in the treatment of patients with
AD.
tem cell therapy in acute myocardial ischemia—
reclinical. The mechanisms by which stem cell therapy
as improved LV function and remodeling after acute MI
ould be important to delineate. Payne et al. (125) hypoth-
sized that direct injection of muscle-derived stem cells
MDSCs) in the ischemic milieu has beneficial paracrine
ffects related to the release of VEGF. Injecting MDSCs
nto the ischemic zone of immunodeficient (NOD-SCID)
ice induced neovascularization to reduce infarct size,
mprove infarct repair, and attenuate adverse remodeling
ith better preservation of LV function (fractional area
hanges by echocardiography) and less LV dilation over 2
eeks to 12 weeks compared with mice injected with
hosphate-buffered saline. The cardioprotective effects of
DSCs were lost when MDSCs were engineered to
xpress the soluble Flt1, a VEGF antagonist. There was
reater VEGF secretion in MDSCs exposed to hypoxia or
tretch in vitro. The accompanying editorial comment by
ammond (126) notes that although it is not novel to relate
he benefits of stem cell transplantation to angiogenesis
ather than cardiac myocyte regeneration, it has not previ-
usly been shown in such a convincing manner in a clinically
elevant model. There are limitations that remain to be
ddressed, such as the duration of survival of engrafted
DSCs, the duration and sustained release of angiogenic
roteins, the risk of engrafted MDSCs for inducing ven-
ricular tachycardia, and the logistics of preparing autolo-
ous MDSCs that will delay the time of treatment after MI.
evertheless, this is a significant advance for understanding
major (although not necessarily sole) contributing factor
or the cardioprotective effects of stem cell therapy in acute
I and for improving post-MI ventricular remodeling.
ipopolysaccharide binding protein (LBP) as a novel
arker of CAD—human biomarker study. The role of
hronic inflammation in the pathogenesis of atherosclerosis
as been supported by evidence that activation of toll-like
eceptors (TLRs), the sensor of microbial infections in the
nnate immune response, is associated with the development
f atherosclerotic lesions. Although the role of specific
nfectious agents is controversial, TLR4 recognizes lipo-
olysaccharide (LPS) from multiple organisms in the innate
mmune response. This requires initial binding of LPS by
BP, an acute phase reactant, and then the LPS/LBP
omplex is delivered to CD14, which binds to TLR4 on the
ell surface. The roles of TLR4 and CD14 (to a lesser
xtent) in atherosclerosis have been studied, but the utility
f LBP as a biomarker of CAD has not been evaluated.
Lepper et al. (127) found that higher serum LBP was in
72 patients with stable, angiographically proven CAD
ompared with 75 patients without CAD or 20 control
atients with fibromyalgia, but lower than LBP levels in 20
atients with sepsis. On multivariable logistic regression
odels, LBP remained a significant and independent pre-ictor of CAD even after adjusting for age, body mass fndex, other inflammatory markers (interleukin 6 and high-
ensitivity CRP), and known CAD risk factors including
DL, smoking, diabetes, and hypertension. Because LBP is
sensor of circulating LPS, it may be useful as a marker of
ctivation of innate immunity that plays a role in the
athogenesis of atherosclerosis that differs from the risks
ssociated with other biomarkers of inflammation.
oxorubicin-induced cardiomyopathy—preclinical
tudy. The clinical utility of doxorubicin is limited by
ardiotoxic side effects with dose-dependent induction of an
rreversible cardiomyopathy that causes HF. Mukho-
adhyay et al. (128) evaluated a novel therapeutic approach
f targeting the endocannabinoid system to protect against
oxorubicin-induced cardiomyopathy in a mouse model.
ndocannabinoids have cardiodepressant effects mediated
y the cannabinoid-1 receptor (CB1), and effective CB1
ntagonists are available. Mice develop a cardiomyopathy 5
ays after a single intraperitoneal injection of doxorubicin,
haracterized by decreased systolic function and diastolic im-
airments. Pretreatment with 2 CB1 antagonists, rimonabant
r AM281, immediately before and for 5 days after doxorubi-
in, attenuated the development of doxorubicin-induced car-
iomyopathy and apoptosis in vivo. In vitro, doxorubicin
nduced apoptosis in a H9c2 myocardial cell line and increased
ne of the natural ligands of CB1 (anandamide, but not
-arachidonoylglycerol), which were blocked by pretreatment
ith rimonabant or AM281. These results suggest that CB1
ntagonists may be a novel therapeutic approach for treating
oxorubicin-induced cardiomyopathy.
Fajardo and Bernstein (129) recognize the novelty of
argeting the endocannabinoid system to reduce doxorubi-
in cardiotoxicity in an accompanying Editorial Comment,
ut note that further studies are needed to determine the
echanisms for the cardioprotective effects of CB1 inhibition.
apid cooling of the heart for cardioprotective effects—
reclinical study. Myocardial hypothermia during myocar-
ial ischemia has powerful cardioprotective effects to limit
nfarct size, but the maximal benefits have been difficult to
chieve because of technical limitations in achieving hypo-
hermia with sufficient rapidity. Tissier et al. (130) used a
ovel approach of total liquid ventilation (TLV) with cooled
erfluorocarbon to decrease left atrial temperatures to 32°C
ithin 5 min in intubated rabbits undergoing 30 min of
schemia and 3 h of reperfusion. Rapid cooling of the heart
uring ischemia reduced infarct size by 90%, whereas
ypothermia during reperfusion was ineffective. This unique
pproach takes advantage of the large thermal mass for
xchange with the central circulation. Perfluorocarbons are
table, inert compounds with low surface tension that
ermit effective gas exchange. Partial liquid ventilation
breathing an air–perfluorocarbon mixture) has been used
afely compared with conventional mechanical ventilation in
linical trials with acute respiratory distress syndrome. The
equirement for intubation and mechanical ventilation
ould delay definitive therapy and may make it unsuitableor primary PCI, but liquid ventilation could be applied
r
i
h
i
t
h
h
D
a
m
a
d
c
s
g
w
w
p
s
s
u
s
m
f
a
T
b
r
P
s
e
s
v
f
r
d
a
(
i
h
b
H
A
b
s
o
s
p
O
f
l
n
p
p
C
t
i
a
g
f
R
f
i
b
p
f
c
t
(
n
I
t
I
d
V
c
s
5
m
p
w
a
d
t
t
l
r
h
t
p
T
c
l
d
s
U
A
F
T
i
v
l
t
T
u
(
p
t
504 DeMaria et al. JACC Vol. 51, No. 4, 2008
Highlights From JACC 2007 January 29, 2008:490–512eadily in patients who are already intubated and mechan-
cally ventilated. This could be used to induce therapeutic
ypothermia in patients with post-operative MI or to
nduce rapid myocardial hypothermia in patients resusci-
ated after cardiac arrest to limit infarct size, which may
ave additive benefits to the neuroprotective effects of
ypothermia
irect coronary blood flow measurements—preclinical
nd clinical study. Direct volumetric blood flow measure-
ent in selective coronary arteries in humans has remained
n elusive but important goal. Aarnoudse et al. (131)
eveloped a thermodilution-based method for measuring
oronary blood flow using a 2.8-F infusion catheter and a
tandard 0.014-inch sensor-tipped pressure/temperature
uidewire. This method for measuring coronary blood flow
as validated in dogs, and was reproducible and correlated
ell with absolute coronary blood flow measured by flow
robe and despite varying degrees of coronary artery steno-
is, infusion rates, and different positions of the temperature
ensor. Preliminary studies were performed in 35 patients
ndergoing intracoronary catheter procedures. Because ab-
olute coronary flow measurements are not possible, this
ethod was indirectly validated by measuring coronary
ractional flow reserve during adenosine-induced hyperemia
denosine or before and after stenting of coronary stenoses.
his study provides a novel method for direct volumetric
lood flow measurements that is accurate, feasible, and
eproducible with potential application in humans.
leiotropic effects of lipid lowering agents—clinical
tudy. The pleiotropic effects of lipid-lowering agents were
xamined by Piorkowski et al. (132) in 56 patients with
table CAD randomized to receive either 40 mg/day ator-
astatin or 10 mg/day atorvastatin plus 10 mg/day ezetimibe
or 4 weeks. Although both treatments produced a compa-
able decrease in LDL cholesterol, monotherapy with high-
ose atorvastatin also decreased in vitro platelet activation
nd aggregation and lowered plasma chemokine levels
RANTES, a measure of in vivo platelet activation and
nflammation). This suggests that higher statin doses may
ave platelet inhibitory pleiotropic effects that may be
eneficial in patients with CAD.
eart Rhythm Disorders
miodarone-induced thyrotoxicosis. An important paper
y Conen et al. (133) draws attention to the potentially fatal
equelae of amiodarone-induced thyrotoxicosis. In a series
f 84 cases, the investigators found a 50% incidence of
erious events including death, heart transplantation, hos-
italization for HF, MI, stroke, and other hospitalizations.
ral prednisone did not speed normalization of thyroid
unction and was associated with worse outcome, particu-
arly after 1 year. These data raise awareness of the serious-
ess of amiodarone-induced thyroid abnormalities and the
otential need for long-term clinical follow-up of these
atients. nongenital LQTS. Little information is available to help
he cardiologist manage the risk for sudden death of
ndividuals who survive adolescence to present with LQTS
s adults. Sauer et al. (134) addressed this issue in 812
enotyped individuals in whom clinical data were available
rom ages 18 years to 40 years in the International Long QT
egistry. Syncope, cardiac arrest, and sudden death during
ollow-up were predicted by female gender, longer QTc
nterval, LQT2 (vs. LQT1 or LQT3) and cardiac events
efore age 18 years. Surprisingly, genotype alone did not
redict life-threatening arrhythmias. These factors differ
rom previous reports, suggesting that some clinical features
onfer age-dependent risk. Another notable finding was
hat beta-blocker use, modeled in time-dependent fashion
i.e., only for years of usage per patient) reduced fatal or
ear-fatal cardiac events by 60%.
mplantable defibrillators and safety of driving. A ques-
ion asked of many physicians is whether it is safe for their
CD patients to return to driving. Albert et al. (135) used
ata from the multicenter prospective TOVA (Triggers of
entricular Arrhythmias) cohort to study whether driving a
ar is associated with increased risk of appropriate ICD
hocks. In 1,188 ICD recipients followed up for a median of
62 days, 80% of all participants and 75% of those within 6
onths of implant self-reported driving a car at least once
er week. Among those who received ICD shocks, shocks
ere twice as likely within 1 h of driving as during other
ctivities. Risk was actually higher in the 30 min after
riving than during driving, but remained low in absolute
erms (1 episode per 25,116 person-hours of driving). Thus,
he risk of ICD shocks causing a motor vehicle accident is
ow; indeed, only 1 of 7 shocks that did occur while driving
esulted in an accident. Finally, there were trends toward
igher risks of shocks among recent ICD recipients and
hose with prior ICD therapy, supporting guidelines for a
eriod of driving abstinence for these individuals.
he risk for lethal ventricular arrhythmias. The search
ontinues for strategies to improve risk stratification for
ethal ventricular arrhythmias beyond the presence of re-
uced LVEF and symptomatic HF. This was the focus of
everal articles published in the Journal this year. Salerno-
riarte et al. (136) published the primary results from the
LPHA (T-Wave Alternans in Patients With Heart
ailure) study, a prospective study of the ability of
-wave alternans (TWA) to predict arrhythmic events in
ndividuals with nonischemic cardiomyopathy. The in-
estigators studied 446 individuals with LVEF of 40% or
ess in New York Heart Association functional classes II
o III. Over 19 months of follow-up, patients who tested
WA negative had a significantly lower rate of ventric-
lar arrhythmias (1.6%) than those with abnormal TWA
6.5%). Although these patients had a lower than ex-
ected event rate overall, this result is particularly impor-
ant because TWA has had mixed success in patients with
onischemic cardiomyopathy.
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January 29, 2008:490–512 Highlights From JACC 2007Extending the link between repolarization variations and
rrhythmic risk, Iacoviello et al. (137) studied ambulatory
lectrocardiogram (ECG) indexes in 179 nonischemic car-
iomyopathy patients with LVEF 34 10%. Nonsustained
entricular tachycardia and steeper QT/RR slope (QT
ynamicity) identified patients at particularly high risk for
rrhythmic events over a mean follow-up of 39 months. The
T/RR slope is the noninvasive analogue of action poten-
ial duration restitution. Patients with higher QT/RR slope
0.19) had higher arrhythmic risk than those with a
hallower slope. Notably, this study suggests that abnormal
T dynamics can stratify arrhythmic risk beyond the
raditional high-risk group because nearly half of the study
opulation had LVEF 35%.
Risk stratifying patients with moderately reduced LVEF
as also the focus of the REFINE (Risk Estimation
ollowing Infarction, Noninvasive Evaluation) study by
xner et al. (138). In this study, 322 patients with mildly
educed LVEF (50%, median 40%) were enrolled within
week of MI and received serial echocardiography and
oninvasive risk assessments. No risk factor predicted events
f measured within the first 4 weeks, yet many were predictive
f measured after 10 to 14 weeks. Notably, the 20% of patients
ith impaired heart rate turbulence on ambulatory ECGs,
bnormal T-wave alternans, and LVEF that remained below
0% had a risk for cardiac death or arrest 5.2 times higher than
emaining patients. These data are among the first to combine
isk factors, and the above constellation of risk factors identi-
ed 52% of at-risk individuals.
An interesting clinical study provided data to support a
imilar mechanism for outflow tract-related premature ven-
ricular contractions, nonsustained VT, and sustained VT.
im et al. (139) performed electrophysiologic study on 127
uch patients, of whom 36 presented with sustained mono-
orphic VT, 46 with nonsustained VT, and 45 with single
remature ventricular contractions. All groups showed sim-
lar anatomic preferences (RV outflow tract in 82%) and
uppression by adenosine and, when sustained tachycardia
as induced, similar response to catecholamines, vagal
aneuvers, adenosine, and verapamil.
romise and pitfalls of CRT. Cardiac resynchronization
herapy is now mainstream therapy for patients with signif-
cant HF, reduced LVEF, and ventricular dyssynchrony.
everal studies in the Journal extended our understanding of
ts benefits. Yannopoulos et al. (140) studied atrial tachyar-
hythmias (AT) in 28 patients before and for 18 months to
4 months after CRT. Compared with 3 months pre-CRT,
t 1 year post-CRT patients were more likely to be free of
T (90% vs. 14%, p  0.001), and thus to have fewer
pisodes of AT of shorter duration. These patients also
xperienced improved LVEF and fewer hospitalizations.
lthough these data require confirmation in larger studies,
hey suggest that CRT-related improvements in ventricular
erformance may also lead to atrial reverse remodeling.
iagnosing intermittent arrhythmias. A common andometimes frustrating clinical problem is how best to fivaluate patients with recurrent palpitations. Giada et al.
141) compared implantable loop recorders (ILR) versus an
ggressive diagnostic protocol in 50 patients with recurrent
alpitations. The ILRs were implanted for 1 year, whereas
he aggressive protocol included 24-h ambulatory ECG
onitoring, 4-week ambulatory ECG monitoring, and
nvasive electrophysiology study. The investigators made
iagnoses in 21% of patients in the aggressive versus 73% in
he ILR groups, translating into cost savings for the ILR
pproach.
echanistic insights into focal atrial tachycardia. Focal
T that terminates with adenosine likely reflects triggered
r enhanced automatic mechanisms, yet it is unclear
hether adenosine-insensitive AT reflects micro–re-entry
r arises from distinct anatomic sites. Markowitz et al. (142)
tudied the mechanism of focal AT in 80 patients. Six cases
8%) that were adenosine-insensitive localized near pulmo-
ary veins and in right atrium, distinct from adenosine-
ensitive cases, which were distributed more widely. Con-
istent with micro–re-entry, adenosine-insensitive sites
ften showed fractionated electrograms, activity accounting
or up to 69% of cycle length, and entrainment with
ost-pacing intervals equal to the tachycardia cycle length.
hese data provide direct evidence for de novo micro–re-
ntry in human atria, arising at different anatomical sites of
riggered or automatic AT.
The use of oral anticoagulants in women has become a
omewhat controversial issue in several recently published
tudies. A paper by Dagres et al. (143), from the Euro Heart
urvey, raised significant concerns regarding the potential
isk for stroke in women with atrial fibrillation. The
nvestigators suggest that the recent CHF, hypertension,
ge 75 years, diabetes, stroke or transient ischemic attack
troke risk classification scheme (144) and the recently
evised American College of Cardiology/American Heart
ssociation/European Society of Cardiology guidelines
lassifying female gender into the “less validated or weaker
isk factors” (145) may have inappropriately de-emphasized
emale gender as an independent stroke risk factor. Dagres
t al. (143) analyzed data from 5,333 atrial fibrillation
atients (42% female) enrolled in the study over a 10-month
eriod. Symptomatic women and men received similar
reatment with respect to rate versus rhythm control.
omen underwent cardioversion less frequently than men
22% vs. 28%, p  0.001), but oral coagulant use was
dentical (65%) in both genders. One-year overall outcome
as similar, but women had a higher stroke rate (odds ratio
.83, p  0.019), a difference attributed to a higher stroke
ate in women who did not receive oral anticoagulation,
ho had at least 1 stroke risk factor, and who were
ndergoing rhythm control (5% vs. 1.2%, p  0.006). No
ifference was observed in women receiving rate control
nly. The investigators concluded that female gender should
e an independent risk factor for stroke, warranting appro-
riate, consistent oral anticoagulation in women with atrial
brillation.
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Highlights From JACC 2007 January 29, 2008:490–512The role of the autonomic system, particularly the para-
ympathetic system, in the initiation and maintenance of
trial fibrillation has recently become an area of significant
esearch interest. Lellouche et al. (146) studied left atrial
ndocardial electrogram characteristics during sinus rhythm
t 1,662 ablation sites in 30 patients undergoing ablation for
aroxysmal atrial fibrillation, in an attempt to correlate these
haracteristics with parasympathetically mediated changes
n sinus rate (20% decrease) or atrio-His interval (10 ms
ncrease). Previous studies have suggested that complex
ractionated atrial electrograms, observed in many patients
ndergoing ablation for atrial fibrillation, may physically
o-locate with areas of local parasympathetic innervation,
nd that their ablation may eliminate recurrence of atrial
brillation during long-term follow-up (147–150). The
nvestigators also studied the effects of intravenous adeno-
ine in patients with paroxysmal atrial fibrillation or acces-
ory pathway mediated supraventricular tachycardia, in-
ended to mimic the effects of acetylcholine signaling in
yocytes. They also mathematically modeled the effects of
denosine and the effects of fibrosis on left atrial electrogram
haracteristics to determine whether abnormal left atrial
lectrograms similar to those observed spontaneously could
e induced with such physiological manipulation. The
nvestigators observed normal electrograms at 732 sites,
ow-amplitude fractionated electrograms at 667 sites, high-
mplitude fractionated electrograms at 263 sites, and a
arasympathetic response at 184 (11%) sites in 29 patients
97%). The observation of a parasympathetic response,
lowing of sinus rate, and prolongation of HV interval was
trongly associated with sites with high-amplitude fraction-
ted electrograms (sensitivity 72%, specificity 91%), which
he investigators characterized as having multiple deflec-
ions (4), high amplitude (0.7 mV), and prolonged
uration (40 ms). They also noted that these sites were
ound predominately in the posterior left atrial wall. They
lso showed that adenosine administration could increase
he number of electrogram deflections, mimicking those
een spontaneously in patients undergoing ablation for atrial
brillation, although it did not affect electrogram amplitude
r duration. Mathematical modeling of the effects of aden-
sine produced high-amplitude fractionated electrograms
imilar to those observed spontaneously in patients showing
sympathetic response at such sites during ablation,
hereas modeling of fibrosis in a 2-dimensional patch of
issue produced low-amplitude fractionated electrograms
imilar to those observed in patients at sites where no
ympathetic response was observed during ablation. The
nvestigators concluded from the findings that normal
lectrograms must obviously arise from normal tissue, and
hat low-amplitude fractionated electrograms may arise
rom areas of fibrosis and may or may not be appropriate
ites to ablate. However, high-amplitude fractionated elec-
rograms, a larger percentage of which were associated with
parasympathetic response when ablated, may be attribut-ble to local effects of acetylcholine in left atrial tissue, rresumably resulting from a higher density of local para-
ympathetic innervation. The investigators did not report
hether ablation at sites with high-amplitude fractionated
lectrograms influenced long-term efficacy of ablation in
heir atrial fibrillation patients, although previous reports
ave suggested a benefit of ablating sites associated with a
arasympathetic response (151). Furthermore, whether
arasympathetic stimulation plays a role in initiation or
aintenance of atrial fibrillation cannot be determined from
his study.
The indications for ICD implantation in patients with
educed LVEF 35% have expanded as a result of recent of
rimary prevention trials of sudden cardiac death, including
he MADIT II (Multicenter Automatic Defibrillator Im-
lantation Trial), MUSTT (Multicenter UnSustained
achycardia Trial), and SC-HeFT (Sudden Cardiac Death
n Heart Failure Trial) studies (152–154). However, in
hese studies a large percentage of patients derived no
enefit from ICD therapy. Chow et al. (155) evaluated the
ole of microvolt T-wave alternans testing to identify
atients with ischemic cardiomyopathy and LVEF 35%
ho would be most likely to benefit from ICD therapy for
revention of sudden death. The investigators evaluated 768
atients with ischemic cardiomyopathy and LVEF 35%
nd no prior sustained ventricular arrhythmias, of whom
92 (51%) underwent ICD implantation. Patients were
ollowed up for 27  12 months. The investigators identi-
ed a total of 514 (67%) patients with non-negative micro-
olt T-wave alternans (MTWA) test results. After multi-
ariable adjustment, ICDs were associated with a lower
ll-cause mortality in MTWA non-negative patients (haz-
rd ratio [HR] 0.45, 95% confidence interval [CI] 0.27 to
.76, p 0.003), but not in MTWA-negative patients. The
ortality benefit seemed to be predominately mediated
hrough arrhythmic mortality reduction (HR 0.30, 95% CI
.13 to 0.68, p  0.004). The number of patients that
eeded to be treated with ICD therapy for 2 years to save 1
ife was 9 among MTWA non-negative versus 76 among
TWA-negative patients. The investigators concluded
hat MTWA testing was a useful adjunctive risk stratifica-
ion strategy to simple LVEF cutoffs for identification of
atients with ischemic cardiomyopathy and LVEF 35%
ho would be most and least likely to benefit from ICD
mplantation, with potential national policy implications for
CD coverage.
rogress in cell therapy. Sufficient data using cell therapy
n clinical trials has accrued to provide the basis for the first
ystematic reviews and meta-analyses of the results to date.
ipinski et al. (156) reviewed 698 patients in 10 studies that
et criteria for outcomes after intracoronary cell therapy
bone-marrow-derived cells or peripheral mononuclear
ells) for acute MI (recent MI, revascularized percutane-
usly, and follow-up 3 months) and concluded that
ntracoronary cell therapy after acute MI results in a modest
mprovement and LVEF with trends in reduced death and
ehospitalization. Despite the potential benefits of cell
t
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January 29, 2008:490–512 Highlights From JACC 2007herapy, Penicka et al. (157) reported the premature termi-
ation of a prospective trial evaluating autologous bone
arrow-derived mononuclear cells in anterior MI. At 4
onths of follow-up there was no significant difference
etween the control and treatment groups in indexes of
ardiac function, but in this small study of 24 patients (14
eceiving cell therapy, 10 placebo control patients) there
ere 4 serious adverse events in the cell therapy group (1
SD rupture/death, 1 stent thrombosis, 1 diagnosis of
iliary carcinoma, and 1 reinfarction). Although inconclu-
ive, these observations may temper enthusiasm for human
ell therapy until further preclinical and clinical studies are
ompleted that address a number of important clinical and
ethodological questions: What are the risks of cell harvest
nd the risks associated with infusion? What is the most
ppropriate setting for cell therapy? What are the optimal
ells? Is there a rationale for cell choice or mode of delivery?
hich outcome should be used to evaluate this new
pproach?
On a more positive note, progress has been reported in
he strategy of cell therapy for a variety of cardiovascular
isorders this year. In a particularly exciting preclinical
tudy, Caspi et al. (158) showed that grafting of human
mbryonic stem cell (hESC)-derived myocytes improved
ardiac function in a rat model of HF after MI. Although
ifferentiated hESCs themselves form teratomas when in-
ected in the myocardium of rats with HF, ex vivo differ-
ntiated hESC cardiomyocytes (CMs) survive, proliferate,
ature, and form gap junctions in the transplanted myo-
ardium. The animals receiving these cells have significant
mprovement in myocardial function that is dependent on
he force generated by the hESC-CMs. Importantly these
ells seem to be devoid of arrhythmogenic potential—a
henomenon that has plagued the use of skeletal myoblasts
rafting for HF. Although there are significant hurdles to
caling up this technique for larger preclinical animal studies
r later in humans (159), these observations and the
otential advantages of this source of cells for an off-the-
helf cell therapy product for HF are exciting to contemplate.
Other noteworthy findings in the field of cell therapy
nclude the observation in a rat model that recipient age
etermines cardiac improvement after skeletal myoblast
mplantation, likely because of reductions in the cardiac and
ystemic responses to the transplant in the older animals
160). In a human study, Kissel et al. (161) examined
hether reduced levels of circulating endothelial progenitor
ells in CHF are primary or secondary to exhaustion of
ematopoietic stem cells in the bone marrow. Importantly,
hey found that ischemic cardiomyopathy is associated with
elective impairment of progenitor cell function in the bone
arrow and in the periphery.
One of the more stunning clinical findings was the report
y Wang et al. (162) that transplantation of autologous
ndothelial progenitor cells (EPCs) may provide a clinical
enefit to patients with pulmonary artery hypertension in an
CT. Sixteen patients with pulmonary artery hypertension geceived EPCs, and 15 received conventional therapy
which does not include epoprostenol) in China. In this
mall study exercise capacity, pulmonary artery pressure,
ardiac output, and pulmonary vascular resistance were
mproved in the EPC-treated group. Presumably endothe-
ial repair mechanisms are at work, and improved endothe-
ial function is the mechanistic basis for this important
bservation. But plasma markers of endothelial function
ere not measured before and after therapy (163). In this
niformly fatal disease, the notion of EPC therapy in
ombination with other relevant modalities targeting the
ndothelial cell is a very exciting prospect.
echanisms of dilated cardiomyopathy (DCM). Two
apers are notable for their insights into novel mechanisms
nderlying HF and the potential to point to novel thera-
eutic modalities. Staudt et al. (164) examined the ability of
ntibodies isolated from the plasma of 11 patients with
CM to affect the function of adult rat cardiomyocytes and
he dependency of the effects on calcium transients and cell
hortening on Fc receptors. In an elegant series of experi-
ents, they report the novel finding that DCM-IgG-
(ab=)2 bind to cardiac antigens and that their Fc portion
hen bound to a novel Fc gamma receptor on cardiomyo-
ytes results in a negative inotropic effect. Thus Fc gamma
eceptors may have a role in DCM and other immune-
ediated cardiac diseases.
In another study, Hikoso et al. (165) investigated whether
nhibition of apoptosis (specifically inhibiting apoptosis
ignal-regulating kinase 1 [ASK1]) would attenuate the
rogression of HF in the TO-2 hamster model of hereditary
ilated cardiomyopathy. Using transcoronary gene transfer
f a dominant-negative ASK1 deletion mutant, they
howed that indeed reduced ASK1 activity results in sup-
ressed progression of chamber dilatation, impairment of
ontractile and relaxation function, and fibrosis. These
nding add additional evidence to the importance of tar-
eting signaling pathways medicating apoptosis for the
reatment of HF.
ardiovascular genomics. In 2007, the Journal continued
ts series begun in 2006 on the prospects of genomics for
ersonalized cardiovascular medicine. The field of genetics
nd genomics of cardiovascular disease continues to unfold
apidly, with many potential and several well established
ultimarker panels moving into daily practice of CVD
isease management and prevention. Genetic findings in
007 were remarkable, and the complexity of integration of
hese tools into patient care has also evolved. Genomics
ontinues to be a key strategy in the diagnosis, prognosis,
nd management of patients with cardiovascular disease.
ith the U.S. Department of Health and Human Services
ommitment to personalized medicine (166) and the more
idespread access of genomic technologies to clinical investi-
ators, there will undoubtedly be more to report in 2008 and
eyond in this exciting area of medicine—cardiovascular
enomic medicine.
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